Theravance Biopharma Inc. (TBPH)
NASDAQ · Healthcare
Theravance Biopharma Inc. EBITDA 2012–2025
Theravance Biopharma Inc. annual/quarterly ebitda history and growth rate from 2012 to 2019. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Theravance Biopharma Inc. ebitda for the quarter ending March 31, 2019 was -72.3 M, a 13.10% increase year-over-year.
- Theravance Biopharma Inc. ebitda for the twelve months ending March 31, 2019 was -235.0 M.
- Theravance Biopharma Inc. annual ebitda for 2018 was -235.6 M, a 8.01% decrease from 2017.
- Theravance Biopharma Inc. annual ebitda for 2017 was -256.1 M, a 44.40% increase from 2016.
- Theravance Biopharma Inc. annual ebitda for 2016 was -177.3 M, a 0.87% decrease from 2015.
- Theravance Biopharma Inc. annual ebitda for 2015 was -178.9 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Theravance Biopharma Inc. EBITDA — FAQ
Theravance Biopharma Inc. (TBPH) ebitda over the last 14 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see TBPH's ebitda history?
The chart and table above show Theravance Biopharma Inc.'s ebitda by year and by quarter, including the growth rate.